Aug 2026· Journal of the National Cancer Institute· 0 citations
Medicine
TL;DR
ARCAD-derived SCAs reliably reproduced control-arm OS and benchmark treatment-effect estimates from landmark RCTs in mCRC, and supports benchmarking, trial design, and exploratory analyses when conventional control arms are impractical.
Strict-primary analyses did not demonstrate a consistent or precise early-endpoint–OS relationship, andarse later windows and uncertainty in both treatment-effect estimates preclude surrogate validation.
Si-Rui Tang, Hui-Ran Zang, Lin-Han Mao et al.· The Oncologist· 0 citations
Improvements in RFS associated with active adjuvant chemotherapy regimens are driven by early changes in recurrence dynamics, which may provide in vivo understanding of residual tumor cell populations after curative-intent resection and how chemotherapy can be best used to prevent recurrence.
Jennie Choe, Sreya Sanyal, Ying-Ting Zhang et al.· Journal of Surgical Research· 0 citations
Background Recurrent or refractory glioblastoma has a poor prognosis, and no universally accepted standard treatment has been established. Randomized evidence is fragmented, making pairwise comparisons insufficient. This study aimed to compare available treatments using a frequentist network meta-analysis. Methods PubM...
Hao Zhang, Lei-Lei Sun, Zhi-He Yun et al.· Frontiers in Neurology· 0 citations
Abstract Designing phase III oncology trials to demonstrate overall survival (OS) superiority may be challenging due to sample size, follow-up time, resources, and costs as compared to trials evaluating intermediate endpoints, which may or may not be reliable surrogates of OS. In this study, we investigate at scale the...
A. Sherry, N. Meimoun, A. Miller et al.· The Oncologist· 0 citations
Background Randomized evidence for immune checkpoint inhibition in resectable non-small-cell lung cancer has progressed from pathological response to mature survival outcomes. We examined exploratory directional alignment across endpoints and quantified clinical yield, treatment burden, and the extent of perioperative...
J. Dai, Meng-Ni Liu, Hu Li et al.· Frontiers in Pharmacology· 0 citations
External control (EC) arms using routine data can be used as comparators in clinical trials under certain conditions. The objective of this study was to assess the ability of an EC arm to replicate outcomes of a randomized controlled trial (RCT) arm receiving the same treatment strategy in advanced stage classical Hodg...
O. Febvey-Combes, Cédric Rossi, B. Kassai et al.· Clinical pharmacology and th...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.